Longitudinal Circulating Tumor DNA Analysis in Blood and Saliva for Prediction of Response to Osimertinib and Disease Progression in EGFR-Mutant Lung Adenocarcinoma

SIMPLE SUMMARY: ctDNA assay is a promising non-invasive method to detect genomic alterations associated with lung cancer. In this prospective study of 25 patients with EGFR-mutant lung adenocarcinoma receiving osimertinib, ctDNA progression predated radiographic progression by 118 days in 11 of 20 p...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Chul, Xi, Liqiang, Cultraro, Constance M., Wei, Fang, Jones, Gregory, Cheng, Jordan, Shafiei, Ahmad, Pham, Trinh Hoc-Tran, Roper, Nitin, Akoth, Elizabeth, Ghafoor, Azam, Misra, Vikram, Monkash, Nina, Strom, Charles, Tu, Michael, Liao, Wei, Chia, David, Morris, Clive, Steinberg, Seth M., Bagheri, Hadi, Wong, David T. W., Raffeld, Mark, Guha, Udayan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268167/
https://www.ncbi.nlm.nih.gov/pubmed/34283064
http://dx.doi.org/10.3390/cancers13133342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268167/
https://www.ncbi.nlm.nih.gov/pubmed/34283064
http://dx.doi.org/10.3390/cancers13133342

Ejemplares similares